Paid Clinical Trials in San Diego, CA

Browse 99 Paid Studies San Diego Across 919 Cities
61 Phase 3 Trial · 5210 Paid Studies San Diego Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Paid Clinical Trials in San Diego, CA

Reviewed by Michael Gill, B. Sc.

Image of 1 Site in Fountain Valley, United States.

Farudodstatfor Alopecia Areata

Fountain Valley, CA

This trial will measure if a drug can help adults with Alopecia Areata regain lost hair on their scalp.

1 Site (+19 Sites)Chief Medical Officer

Image of Pinnacle Research Group in Anniston, United States.

MRNA-1010for Flu

This trial tests the safety and effectiveness of a new vaccine for flu A & B strains.

Waitlist Available

Pinnacle Research Group (+60 Sites)ModernaTX, Inc.

Image of Research Site 24 in Huntsville, United States.

BLI5100 High Dosefor Non-erosive Reflux Disease

This trial will evaluate the safety & efficacy of oral BLI5100 given daily for 4 wks, then safety for 20 wks, for those with NERD.

Research Site 24 (+96 Sites)Leah HollinsBraintree Laboratories

Image of Central Research Associates Inc in Birmingham, United States.

Afluria® Quadrivalentfor Respiratory Syncytial Virus

This trial is testing the safety and effectiveness of a new vaccine for RSV (respiratory syncytial virus) that is given with either a seasonal flu vaccine or a new vaccine for SARS-CoV-2 (the virus that causes COVID-19).

Waitlist Available

Senior-friendly

Central Research Associates Inc (+63 Sites)ModernaTX, Inc.

Image of Children's Hospital Los Angeles in Los Angeles, United States.

Afrezzafor Type 1 Diabetes

Los Angeles, CA

This trial is testing the efficacy and safety of Afrezza, a inhaled insulin, in children with type 1 or 2 diabetes. The trial has a screening and run-in period of up to 5 weeks, followed by a 26-week randomized treatment period, during which subjects will receive either Afrezza or a rapid-acting insulin injection. All subjects will then enter a 26-week treatment extension, during which they will receive Afrezza. The trial will conclude with a 4-week follow-up period.

FDA Approved Drug

Children's Hospital Los Angeles (+56 Sites)Karen JaffeMannkind Corporation

Image of Sarah Cannon Research Institute (Florida Cancer Specialists) in Sarasota, United States.

ERAS-601for Solid Tumors

This trial is testing the safety and effectiveness of a new drug, ERAS-601, for treating advanced or metastatic solid tumors.

FDA Approved Drug

Sarah Cannon Research Institute (Florida Cancer Specialists) (+12 Sites)Les Brail, PhDErasca, Inc.

Image of Homestead Associates in Research in Miami, United States.

Twice Daily 90 Mg Hydrocortisone Acetate Suppository Administered With Sephure Applicatorfor Ulcerative Proctitis

This trial is testing a new way to deliver a medication for ulcerative colitis via a suppository. The study will compare the safety and effectiveness of two different doses given with a new applicator.

FDA Approved Drug

Homestead Associates in Research (+29 Sites)Karthik Devarajan, MDCristcot LLC

Image of Investigational Site Number 8400022 in Little Rock, United States.

Dupilumab SAR231893for Chronic Obstructive Pulmonary Disease

Little Rock, AR

This trial is testing the efficacy of a new drug, dupilumab, for treating moderate or severe COPD. The primary objective is to measure the annualized rate of acute COPD exacerbation (AECOPD) and the secondary objectives are to assess the effects of the drug on lung function and health-related quality of life. The trial will also evaluate the safety and tolerability of the drug and the incidence of antidrug antibodies (ADA).

Waitlist Available

FDA Approved Drug

Investigational Site Number 8400022 (+53 Sites)Clinical Sciences & OperationsSanofi

Image of ForCare Clinical Research in Tampa, United States.

Abrocitinib 200 Mgfor Atopic Dermatitis

This trial is studying whether a new drug, abrocitinib, is effective and safe for treating atopic dermatitis in patients aged 12 years and older. The trial consists of an initial treatment period of 92 weeks, followed by a secondary treatment period of variable length during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. There is also a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI.

Waitlist Available

ForCare Clinical Research (+12 Sites)Pfizer CT.gov Call CenterPfizer

Image of University of California San Diego in San Diego, United States.

3b: +UCx No Oral Options (7d)for Kidney Stones

This trial will study the effect of a short course of antibiotics before surgery for patients at a moderately increased risk of postoperative infection.

FDA Approved Drug

University of California San Diego

10 Paid Studies San Diego Near Me

Top Cities for Paid Studies San Diego

Image of San Diego in California.

San Diego

132Active Trials

Rady Children's Hospital - San DiegoTop Active Site

Image of Miami in Florida.

Miami

130Active Trials

University of Miami Miller School of Medicine-Sylvester Cancer CenterTop Active Site

Paid Studies San Diego by Phase of Trial

N/A Paid Studies San Diego

11Active Paid Studies San Diego

11Number of Unique Treatments

233Number of Active Locations

3b: +UCx No Oral options (7d)Connected Catheter Umbilical Cord Milking Transanastomotic Tube (5FR)Active Monitoring Treatment Enhanced Standard-of-Care Positive End-Expiratory Pressure (PEEP)regional nodal XRT Mediterranean Diet Collaborative Decision Skills Training

Most Recent Paid Studies San Diego

Clinical Trial

Began Recruiting Date

Phase

Dose Escalation for Colorectal Cancer

8/29/2023

Phase 1

SSA: Group 1 for COVID-19

8/10/2023

Phase 2 & 3

Lidocaine for Interstitial Cystitis

5/22/2023

Phase 2

Ziltivekimab 15 mg for Heart Failure

5/8/2023

Phase 3

mRNA-1010 for Flu

4/17/2023

Phase 3

About The Author

Michael Gill - B. Sc.

First Published: October 15th, 2021

Last Reviewed: September 26th, 2023

References¹ Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. https://pubmed.ncbi.nlm.nih.gov/16055882² Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. https://pubmed.ncbi.nlm.nih.gov/16055882³ Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. https://pubmed.ncbi.nlm.nih.gov/35622074⁴ Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. Review. https://pubmed.ncbi.nlm.nih.gov/35622074⁵ Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. https://pubmed.ncbi.nlm.nih.gov/19720809⁶ Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. https://pubmed.ncbi.nlm.nih.gov/17132052⁷ Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442. https://pubmed.ncbi.nlm.nih.gov/17132052⁸ Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. https://pubmed.ncbi.nlm.nih.gov/10377201⁹ Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. doi: 10.1136/thx.54.7.581. https://pubmed.ncbi.nlm.nih.gov/10377201¹⁰ Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27. https://pubmed.ncbi.nlm.nih.gov/22743675

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security